Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | BLM | P54132 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | RGS12 | O14924 | 3/20 | 0.52 |
| ▸ | GMNN | O75496 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21484643 | 0.90 | EGFR (0.58) | EGFRERBB2MEN1BLMKMT2A | |
| SCHEMBL21484665 | 0.90 | MRE11 (0.56) | EGFRERBB2MEN1BLMKMT2A | |
| SCHEMBL21484629 | 0.89 | EGFR (0.62) | EGFRERBB2MEN1BLMKMT2A | |
| SCHEMBL21484714 | 0.89 | MRE11 (0.58) | EGFRERBB2MEN1BLMKMT2A | |
| SCHEMBL21484789 | 0.89 | EGFR (0.54) | EGFRERBB2MEN1BLMKMT2A | |
| SCHEMBL21484820 | 0.89 | EGFR (0.54) | EGFRERBB2MEN1BLMKMT2A | |
| SCHEMBL21484888 | 0.88 | EGFR (0.60) | EGFRERBB2MEN1BLMKMT2A | |
| SCHEMBL21484819 | 0.86 | EGFR (0.54) | EGFRERBB2MEN1BLMKMT2A | |
| SCHEMBL21484783 | 0.86 | EGFR (0.55) | EGFRERBB2MEN1BLMKMT2A | |
| SCHEMBL21484889 | 0.85 | EGFR (0.54) | EGFRERBB2MEN1BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2023-02-21 | — | — | US | disclosed |
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2023-02-21 | — | — | US | disclosed |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2022-01-06 | — | — | US | disclosed |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2022-01-06 | — | — | US | disclosed |
| EP-3556755-B1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | UNIV MASARYKOVA (CZ) | 2021-11-17 | — | — | EP | disclosed |
| EP-3556755-B1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | UNIV MASARYKOVA (CZ) | 2021-11-17 | — | — | EP | disclosed |
| CN-112313229-A | Substituted aminothiazoles as inhibitors of nucleases | 马萨里克大学 | 2021-02-02 | — | — | CN | disclosed |
| WO-2019201865-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019201865-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2019-10-24 | — | — | WO | disclosed |
| EP-3556755-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | Masarykova univerzita (CZ) | 2019-10-23 | — | — | EP | disclosed |
| EP-3556755-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | Masarykova univerzita (CZ) | 2019-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | RNASEH1, DNASE1, FEN1 | EGFR 1661/4885ERBB2 2095/4885MEN1 1727/4885 |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | RNASEH1, DNASE1, FEN1 | EGFR 1661/4885ERBB2 2095/4885MEN1 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.